Codiak BioSciences IPO

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.

Register for Details

For more details on financing and valuation for Codiak BioSciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Codiak BioSciences

Forge green plus iconForge green minus icon

What is Codiak BioSciences's IPO price?

Codiak BioSciences's IPO price is $0.057 as of 4/4/23.
Forge green plus iconForge green minus icon

What is Codiak BioSciences's funding to date?

Codiak BioSciences has raised $168.37MM to date.
Forge green plus iconForge green minus icon

When was Codiak BioSciences founded?

Codiak BioSciences was founded in 2015.

Codiak BioSciences Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
11/29/2017 Series C $76.37MM raised $XXX.XX $XXX.XX
1/26/2016 Series B $61MM raised $XXX.XX $XXX.XX
11/25/2015 Series A $31MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.